CRF, bovine |
Catalog No.GC35748
One-Click Copy Product Info
|
CRF, bovine is an important neuropeptide consisting of 41 amino acids, it is produced by the hypothalamus and is transported to the pituitary, where it triggers the release of adrenocorticotropic hormone (ACTH).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 92307-52-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CRF, bovine is an important neuropeptide consisting of 41 amino acids[1], it is produced by the hypothalamus and is transported to the pituitary, where it triggers the release of adrenocorticotropic hormone (ACTH)[2]. CRF, bovine plays a significant role in social behavior and is commonly utilized in research of various psychiatric disorders, such as depression, anxiety, and substance/alcohol abuse[3][4].
CRF, bovine (0.1µM; 3h) treatment can rapidly stimulated cyclic AMP production, increasing it 4- to 6-fold in 3min and reaching a peak of 10- to 15-fold at 30min in rat anterior pituitary cells[5]. In RAW 264.7 cells, treatment with CRF, bovine at 10nM for 4 hours enhanced the NF-κB-mediated luciferase expression[6].
CRF, bovine play important roles in sociability, intracerebroventricular administration of CRF, bovine (5µg/2µL; 30min) significantly decreased the number of entries and the time of interaction with the unknown male mice[7]. CRF (100ng; icv) consistently decreased immobility in the tail suspension test (TST) and the forced swim test (FST) in unshocked mice[8].
References:
[1]. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981 Sep 18;213(4514):1394-7. doi: 10.1126/science.6267699. PMID: 6267699.
[2]. Hogg JE, Myers J, Hutson PH. The human neuroblastoma cell line, IMR-32, expresses functional corticotropin-releasing factor receptors. Eur J Pharmacol. 1996 Sep 26;312(2):257-61. doi: 10.1016/0014-2999(96)00470-0. PMID: 8894604.
[3]. Matsoukas MT, Panagiotopoulos V, Karageorgos V, et al. Structural and Functional Insights into CRF Peptides and Their Receptors. Biology (Basel). 2024 Feb 13;13(2):120. doi: 10.3390/biology13020120. PMID: 38392338; PMCID: PMC10886364.
[4]. Sanders J, Nemeroff C. The CRF System as a Therapeutic Target for Neuropsychiatric Disorders. Trends Pharmacol Sci. 2016 Dec;37(12):1045-1054. doi: 10.1016/j.tips.2016.09.004. Epub 2016 Oct 4. PMID: 27717506; PMCID: PMC5121012.
[5]. Aguilera G, Harwood JP, Wilson JX, et al. Mechanisms of action of corticotropin-releasing factor and other regulators of corticotropin release in rat pituitary cells. J Biol Chem. 1983 Jul 10;258(13):8039-45. PMID: 6305967.
[6]. Smith EM, Gregg M, Hashemi F, et al. Corticotropin Releasing Factor (CRF) activation of NF-kappaB-directed transcription in leukocytes. Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):1021-36. doi: 10.1007/s10571-006-9040-1. Epub 2006 Apr 22. PMID: 16633893; PMCID: PMC11520635.
[7]. Bagosi Z, Karasz G, Czébely-Lénárt A, et al. The effects of CRF and urocortins on the sociability of mice. Brain Res. 2017 May 15;1663:114-122. doi: 10.1016/j.brainres.2017.03.003. Epub 2017 Mar 14. PMID: 28315311.
[8]. Swiergiel AH, Leskov IL, Dunn AJ. Effects of chronic and acute stressors and CRF on depression-like behavior in mice. Behav Brain Res. 2008 Jan 10;186(1):32-40. doi: 10.1016/j.bbr.2007.07.018. Epub 2007 Jul 20. PMID: 17716752.
| Cell experiment [1]: | |
|
Cell lines |
Rat anterior pituitary cells |
|
Preparation Method |
Rat anterior pituitary cells were treated with 0.1µM CRF, bovine for 3h. Then the cyclic AMP content was measured. For cyclic AMP measurement, cells were incubated for 30min with 1mM methylisobutylxanthine. Cell suspensions were boiled in equal volumes of PBS for 10min, then cooled and centrifuged at 1500g for 20min, the cyclic AMP content of the supernatant was measured by radioimmunoassay. |
|
Reaction Conditions |
0.1µM; 3h |
|
Applications |
CRF, bovine treatment can rapidly stimulated cyclic AMP production in rat anterior pituitary cells. |
| Animal experiment [2]: | |
|
Animal models |
Male CFLP mice |
|
Preparation Method |
The mice were implanted with a stainless steel Luer cannula aimed at the right lateral cerebral ventricle, the mice were allowed for 5 days to recover after the surgery then treated with CRF, bovine. Thirty minutes after ICV injection of the CRF, bovine mice were investigated in a social interaction test arena. |
|
Dosage form |
5µg/2µL; 30min; icv. |
|
Applications |
CRF, bovine decreased the number of entries and the time of interaction with the unknown male. |
|
References: |
|
| Cas No. | 92307-52-3 | SDF | |
| Formula | C206H340N60O63S | M.Wt | 4697.34 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 212.9 μL | 1.0644 mL | 2.1289 mL |
| 5 mM | 42.6 μL | 212.9 μL | 425.8 μL |
| 10 mM | 21.3 μL | 106.4 μL | 212.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)